| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 242 | 2024 | 544 | 37.680 |
Why?
|
| Carcinoma, Transitional Cell | 96 | 2023 | 192 | 15.810 |
Why?
|
| Cystectomy | 97 | 2024 | 154 | 11.100 |
Why?
|
| Neoplasm Invasiveness | 77 | 2024 | 605 | 5.150 |
Why?
|
| Lymph Node Excision | 32 | 2024 | 157 | 4.550 |
Why?
|
| Neoplasm Recurrence, Local | 62 | 2024 | 1119 | 4.460 |
Why?
|
| BCG Vaccine | 26 | 2024 | 108 | 4.110 |
Why?
|
| Neoadjuvant Therapy | 24 | 2024 | 322 | 3.700 |
Why?
|
| Carcinoma in Situ | 23 | 2024 | 67 | 3.670 |
Why?
|
| Biomarkers, Tumor | 45 | 2024 | 1440 | 3.380 |
Why?
|
| Cystoscopy | 12 | 2021 | 44 | 2.970 |
Why?
|
| Kidney Neoplasms | 18 | 2024 | 429 | 2.630 |
Why?
|
| Neoplasm Staging | 71 | 2024 | 1211 | 2.500 |
Why?
|
| Mitomycin | 6 | 2022 | 49 | 2.470 |
Why?
|
| Carcinoma | 8 | 2021 | 278 | 2.220 |
Why?
|
| Urologic Neoplasms | 9 | 2023 | 41 | 2.150 |
Why?
|
| Cisplatin | 19 | 2024 | 242 | 2.030 |
Why?
|
| Antineoplastic Agents | 33 | 2024 | 1664 | 1.970 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 1231 | 1.810 |
Why?
|
| Urothelium | 16 | 2021 | 60 | 1.810 |
Why?
|
| Humans | 324 | 2024 | 123288 | 1.770 |
Why?
|
| Lymphatic Metastasis | 35 | 2024 | 401 | 1.710 |
Why?
|
| Lymph Nodes | 15 | 2023 | 376 | 1.710 |
Why?
|
| Prostatic Neoplasms | 22 | 2024 | 1525 | 1.700 |
Why?
|
| Ureteral Neoplasms | 8 | 2022 | 24 | 1.640 |
Why?
|
| Aged | 142 | 2024 | 19180 | 1.590 |
Why?
|
| Adjuvants, Immunologic | 17 | 2024 | 376 | 1.580 |
Why?
|
| Aged, 80 and over | 78 | 2024 | 6390 | 1.540 |
Why?
|
| Urinary Bladder | 18 | 2023 | 242 | 1.450 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2021 | 127 | 1.420 |
Why?
|
| Middle Aged | 145 | 2024 | 26095 | 1.410 |
Why?
|
| Prognosis | 65 | 2024 | 4518 | 1.390 |
Why?
|
| Tomography, Optical Coherence | 5 | 2021 | 516 | 1.370 |
Why?
|
| Male | 192 | 2024 | 60346 | 1.330 |
Why?
|
| Nomograms | 7 | 2015 | 36 | 1.250 |
Why?
|
| Carcinoma, Renal Cell | 8 | 2024 | 236 | 1.210 |
Why?
|
| Disease Progression | 35 | 2020 | 2031 | 1.160 |
Why?
|
| Chemotherapy, Adjuvant | 23 | 2024 | 353 | 1.150 |
Why?
|
| Female | 173 | 2024 | 65630 | 1.140 |
Why?
|
| Deoxycytidine | 7 | 2024 | 76 | 1.090 |
Why?
|
| Treatment Outcome | 72 | 2024 | 12176 | 1.080 |
Why?
|
| Hydrogels | 3 | 2021 | 78 | 1.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 25 | 2016 | 182 | 0.980 |
Why?
|
| Genetic Therapy | 8 | 2020 | 680 | 0.980 |
Why?
|
| Clinical Trials as Topic | 15 | 2023 | 1084 | 0.970 |
Why?
|
| Administration, Intravesical | 18 | 2024 | 32 | 0.930 |
Why?
|
| Cadherins | 7 | 2005 | 164 | 0.930 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 5 | 2022 | 24 | 0.880 |
Why?
|
| Prostate | 6 | 2019 | 431 | 0.860 |
Why?
|
| Neoplasm Grading | 13 | 2021 | 266 | 0.850 |
Why?
|
| Tumor Suppressor Protein p53 | 11 | 2018 | 717 | 0.850 |
Why?
|
| Robotics | 2 | 2023 | 106 | 0.830 |
Why?
|
| Robotic Surgical Procedures | 3 | 2023 | 194 | 0.800 |
Why?
|
| Survival Rate | 32 | 2019 | 2005 | 0.780 |
Why?
|
| Muscles | 7 | 2024 | 288 | 0.760 |
Why?
|
| Urinary Diversion | 5 | 2017 | 42 | 0.740 |
Why?
|
| Immunotherapy | 6 | 2023 | 661 | 0.730 |
Why?
|
| Disease-Free Survival | 18 | 2024 | 858 | 0.730 |
Why?
|
| Gels | 1 | 2021 | 68 | 0.730 |
Why?
|
| Urinary Tract | 1 | 2021 | 60 | 0.700 |
Why?
|
| Neoplasm Proteins | 6 | 2014 | 668 | 0.690 |
Why?
|
| Follow-Up Studies | 35 | 2024 | 5061 | 0.690 |
Why?
|
| Transcriptome | 6 | 2019 | 903 | 0.680 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 182 | 0.680 |
Why?
|
| Patient Selection | 6 | 2024 | 683 | 0.670 |
Why?
|
| Drug Carriers | 1 | 2020 | 100 | 0.660 |
Why?
|
| Genomics | 7 | 2020 | 1474 | 0.660 |
Why?
|
| Adult | 87 | 2024 | 29093 | 0.660 |
Why?
|
| Genetic Vectors | 8 | 2020 | 939 | 0.660 |
Why?
|
| Predictive Value of Tests | 19 | 2021 | 2115 | 0.650 |
Why?
|
| Injections, Intradermal | 1 | 2018 | 31 | 0.620 |
Why?
|
| Pelvic Neoplasms | 2 | 2015 | 21 | 0.610 |
Why?
|
| Organ Sparing Treatments | 4 | 2024 | 34 | 0.600 |
Why?
|
| Muscle Neoplasms | 4 | 2015 | 21 | 0.600 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 109 | 0.600 |
Why?
|
| Molecular Targeted Therapy | 3 | 2016 | 351 | 0.600 |
Why?
|
| Survival Analysis | 30 | 2024 | 1473 | 0.590 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 99 | 0.590 |
Why?
|
| Prospective Studies | 19 | 2024 | 6033 | 0.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 1871 | 0.540 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2016 | 10 | 0.530 |
Why?
|
| Vinblastine | 3 | 2015 | 48 | 0.530 |
Why?
|
| Doxorubicin | 5 | 2015 | 300 | 0.530 |
Why?
|
| Urethral Neoplasms | 2 | 2013 | 9 | 0.530 |
Why?
|
| Combined Modality Therapy | 13 | 2021 | 1238 | 0.530 |
Why?
|
| DNA Damage | 5 | 2024 | 513 | 0.530 |
Why?
|
| Carcinoma, Papillary | 4 | 2024 | 77 | 0.530 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 348 | 0.520 |
Why?
|
| Vidarabine | 15 | 2002 | 79 | 0.520 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 2014 | 73 | 0.520 |
Why?
|
| Adenoviridae | 6 | 2024 | 604 | 0.510 |
Why?
|
| Methotrexate | 4 | 2015 | 343 | 0.500 |
Why?
|
| Neoplasm Metastasis | 13 | 2024 | 654 | 0.500 |
Why?
|
| Risk Factors | 34 | 2023 | 10033 | 0.500 |
Why?
|
| Proportional Hazards Models | 16 | 2018 | 1304 | 0.490 |
Why?
|
| Splenomegaly | 2 | 2005 | 34 | 0.490 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2022 | 1081 | 0.490 |
Why?
|
| Urokinase-Type Plasminogen Activator | 3 | 2003 | 41 | 0.480 |
Why?
|
| Societies, Medical | 4 | 2020 | 677 | 0.480 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 495 | 0.480 |
Why?
|
| Occupational Exposure | 2 | 2023 | 128 | 0.480 |
Why?
|
| Prostatectomy | 6 | 2019 | 332 | 0.480 |
Why?
|
| Urinary Reservoirs, Continent | 5 | 2014 | 23 | 0.470 |
Why?
|
| Retinoblastoma Protein | 4 | 2010 | 78 | 0.470 |
Why?
|
| Thymidine Kinase | 7 | 2003 | 95 | 0.460 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 1693 | 0.460 |
Why?
|
| Everolimus | 2 | 2024 | 46 | 0.460 |
Why?
|
| Pelvis | 5 | 2017 | 68 | 0.450 |
Why?
|
| Salvage Therapy | 5 | 2016 | 193 | 0.450 |
Why?
|
| Immunohistochemistry | 17 | 2016 | 1686 | 0.450 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2012 | 45 | 0.450 |
Why?
|
| Indoles | 3 | 2012 | 181 | 0.450 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2004 | 99 | 0.440 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 118 | 0.430 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 111 | 0.430 |
Why?
|
| Retinoblastoma Binding Proteins | 3 | 2024 | 11 | 0.430 |
Why?
|
| Cyclins | 2 | 2004 | 101 | 0.430 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 206 | 0.430 |
Why?
|
| Turkeys | 3 | 2003 | 6 | 0.420 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 88 | 0.420 |
Why?
|
| Interleukin-6 | 4 | 2024 | 410 | 0.420 |
Why?
|
| Preoperative Care | 5 | 2016 | 348 | 0.410 |
Why?
|
| Adenoviruses, Human | 3 | 2012 | 81 | 0.410 |
Why?
|
| Isoenzymes | 2 | 2003 | 225 | 0.410 |
Why?
|
| Biopsy | 10 | 2021 | 1236 | 0.410 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2014 | 60 | 0.400 |
Why?
|
| Endoscopy | 1 | 2014 | 282 | 0.400 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2016 | 67 | 0.400 |
Why?
|
| Anilides | 4 | 2024 | 48 | 0.400 |
Why?
|
| Cell Line, Tumor | 17 | 2024 | 3286 | 0.400 |
Why?
|
| Retrospective Studies | 37 | 2024 | 16081 | 0.390 |
Why?
|
| Surgical Stomas | 1 | 2011 | 8 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2024 | 1008 | 0.390 |
Why?
|
| Kidney | 3 | 2022 | 1342 | 0.380 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2024 | 70 | 0.380 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2001 | 107 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 1251 | 0.380 |
Why?
|
| Mutation | 11 | 2024 | 5766 | 0.370 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2018 | 178 | 0.360 |
Why?
|
| Pyrroles | 2 | 2012 | 178 | 0.360 |
Why?
|
| Prostate-Specific Antigen | 4 | 2024 | 256 | 0.360 |
Why?
|
| Sulfonamides | 2 | 2014 | 259 | 0.350 |
Why?
|
| Multivariate Analysis | 13 | 2014 | 1414 | 0.350 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2020 | 713 | 0.350 |
Why?
|
| Occupational Diseases | 2 | 2008 | 74 | 0.340 |
Why?
|
| Estrogen Receptor alpha | 3 | 2012 | 454 | 0.340 |
Why?
|
| Pyrazoles | 2 | 2014 | 305 | 0.340 |
Why?
|
| Smoking | 8 | 2023 | 1031 | 0.330 |
Why?
|
| Ganciclovir | 4 | 2003 | 102 | 0.330 |
Why?
|
| Chemoprevention | 2 | 2006 | 57 | 0.330 |
Why?
|
| Time Factors | 18 | 2020 | 6223 | 0.320 |
Why?
|
| Nephrectomy | 5 | 2024 | 173 | 0.310 |
Why?
|
| Testicular Neoplasms | 3 | 2000 | 132 | 0.310 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 3 | 2024 | 21 | 0.310 |
Why?
|
| Rhabdomyosarcoma | 2 | 2005 | 200 | 0.300 |
Why?
|
| Urogenital Neoplasms | 2 | 2023 | 15 | 0.290 |
Why?
|
| Metabolome | 4 | 2019 | 294 | 0.290 |
Why?
|
| Tosyl Compounds | 2 | 2024 | 21 | 0.290 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2007 | 54 | 0.290 |
Why?
|
| Fluorescence | 3 | 2014 | 93 | 0.280 |
Why?
|
| Reproducibility of Results | 8 | 2021 | 2845 | 0.280 |
Why?
|
| Genetic Loci | 3 | 2014 | 332 | 0.280 |
Why?
|
| Clinical Medicine | 1 | 2007 | 21 | 0.280 |
Why?
|
| DNA Methylation | 5 | 2023 | 989 | 0.270 |
Why?
|
| Sensitivity and Specificity | 8 | 2012 | 2019 | 0.270 |
Why?
|
| Nitriles | 2 | 2024 | 146 | 0.270 |
Why?
|
| Vena Cava, Inferior | 2 | 2014 | 101 | 0.270 |
Why?
|
| Kidney Pelvis | 3 | 2017 | 44 | 0.270 |
Why?
|
| Receptors, Cell Surface | 3 | 2003 | 469 | 0.270 |
Why?
|
| Atlases as Topic | 2 | 2017 | 16 | 0.260 |
Why?
|
| Pyridines | 2 | 2024 | 224 | 0.260 |
Why?
|
| Postoperative Complications | 5 | 2023 | 3019 | 0.260 |
Why?
|
| Metabolomics | 5 | 2024 | 409 | 0.250 |
Why?
|
| Fatty Acids | 2 | 2019 | 338 | 0.250 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2004 | 96 | 0.250 |
Why?
|
| Instillation, Drug | 2 | 2022 | 7 | 0.250 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 50 | 0.240 |
Why?
|
| Cell Cycle | 3 | 2018 | 618 | 0.240 |
Why?
|
| Receptors, Virus | 1 | 2005 | 103 | 0.240 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2023 | 57 | 0.240 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2024 | 3 | 0.230 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2024 | 93 | 0.230 |
Why?
|
| Triazines | 1 | 2024 | 29 | 0.230 |
Why?
|
| Neoplastic Stem Cells | 2 | 2018 | 295 | 0.230 |
Why?
|
| Glutaminase | 1 | 2024 | 13 | 0.230 |
Why?
|
| Urine | 2 | 2003 | 89 | 0.230 |
Why?
|
| Risk Assessment | 9 | 2024 | 3341 | 0.230 |
Why?
|
| Carbazoles | 2 | 2014 | 32 | 0.230 |
Why?
|
| Estrogen Receptor beta | 3 | 2012 | 79 | 0.230 |
Why?
|
| DNA Repair | 3 | 2018 | 579 | 0.230 |
Why?
|
| Egg Shell | 2 | 2000 | 4 | 0.230 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 93 | 0.230 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2004 | 10 | 0.230 |
Why?
|
| Apoptosis | 8 | 2014 | 1787 | 0.230 |
Why?
|
| Precision Medicine | 2 | 2018 | 308 | 0.230 |
Why?
|
| Plasminogen Activators | 1 | 2003 | 20 | 0.220 |
Why?
|
| Diet | 4 | 2018 | 1133 | 0.220 |
Why?
|
| Integrin beta1 | 1 | 2004 | 54 | 0.220 |
Why?
|
| Ribose | 1 | 2023 | 11 | 0.220 |
Why?
|
| Medical Oncology | 3 | 2017 | 214 | 0.220 |
Why?
|
| Urinary Tract Infections | 2 | 2023 | 295 | 0.210 |
Why?
|
| Glutamine | 1 | 2024 | 207 | 0.210 |
Why?
|
| Animals | 31 | 2024 | 33853 | 0.210 |
Why?
|
| Cell Proliferation | 8 | 2024 | 2297 | 0.210 |
Why?
|
| Cost of Illness | 1 | 2024 | 243 | 0.210 |
Why?
|
| Germinoma | 2 | 2000 | 31 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2024 | 352 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 44 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 32 | 0.210 |
Why?
|
| Incidence | 9 | 2018 | 3055 | 0.200 |
Why?
|
| RNA, Messenger | 6 | 2018 | 2816 | 0.200 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2004 | 244 | 0.200 |
Why?
|
| Regression Analysis | 8 | 2008 | 773 | 0.200 |
Why?
|
| Antigens, Neoplasm | 2 | 2005 | 382 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 2 | 2001 | 456 | 0.200 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2002 | 38 | 0.200 |
Why?
|
| Drug Synergism | 5 | 2014 | 239 | 0.190 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 117 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2024 | 366 | 0.190 |
Why?
|
| Mice | 18 | 2024 | 17557 | 0.190 |
Why?
|
| Aminolevulinic Acid | 2 | 2014 | 9 | 0.190 |
Why?
|
| alpha-Fetoproteins | 2 | 2010 | 131 | 0.190 |
Why?
|
| Raloxifene Hydrochloride | 3 | 2012 | 16 | 0.190 |
Why?
|
| Muscle, Smooth | 2 | 2018 | 136 | 0.190 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2001 | 39 | 0.180 |
Why?
|
| Eggs | 1 | 2000 | 24 | 0.180 |
Why?
|
| Mutation Rate | 2 | 2017 | 66 | 0.180 |
Why?
|
| Avian Sarcoma Viruses | 1 | 2000 | 32 | 0.180 |
Why?
|
| Cohort Studies | 13 | 2019 | 4692 | 0.180 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2000 | 61 | 0.180 |
Why?
|
| Histone Demethylases | 2 | 2017 | 38 | 0.180 |
Why?
|
| Gene Expression Profiling | 6 | 2019 | 1682 | 0.180 |
Why?
|
| Catheters | 1 | 2021 | 89 | 0.180 |
Why?
|
| Israel | 1 | 2020 | 44 | 0.170 |
Why?
|
| Drug Compounding | 1 | 2020 | 34 | 0.170 |
Why?
|
| Folic Acid | 2 | 2018 | 292 | 0.170 |
Why?
|
| Chorionic Gonadotropin | 1 | 2000 | 86 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 576 | 0.170 |
Why?
|
| Urethra | 4 | 2020 | 83 | 0.170 |
Why?
|
| Urologic Surgical Procedures | 1 | 2020 | 58 | 0.170 |
Why?
|
| Polymorphism, Genetic | 4 | 2007 | 807 | 0.170 |
Why?
|
| Case-Control Studies | 13 | 2017 | 3236 | 0.170 |
Why?
|
| United States | 11 | 2021 | 10657 | 0.170 |
Why?
|
| Patient Compliance | 2 | 2014 | 469 | 0.170 |
Why?
|
| Inactivation, Metabolic | 1 | 2019 | 32 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 1340 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 429 | 0.170 |
Why?
|
| Body Weight | 2 | 2000 | 1007 | 0.170 |
Why?
|
| Mitochondria | 1 | 2024 | 676 | 0.170 |
Why?
|
| Blood Glucose | 2 | 2000 | 1124 | 0.160 |
Why?
|
| Ureter | 2 | 2019 | 95 | 0.160 |
Why?
|
| Simplexvirus | 4 | 2003 | 104 | 0.160 |
Why?
|
| Activin Receptors, Type I | 1 | 1999 | 33 | 0.160 |
Why?
|
| Interleukin-2 | 1 | 2000 | 224 | 0.160 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 1268 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 3 | 2014 | 240 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 1690 | 0.160 |
Why?
|
| Genome, Human | 2 | 2017 | 1263 | 0.160 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 25 | 0.160 |
Why?
|
| Counseling | 1 | 2001 | 219 | 0.160 |
Why?
|
| DNA, Neoplasm | 4 | 2023 | 300 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2000 | 269 | 0.160 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 89 | 0.160 |
Why?
|
| Situs Inversus | 1 | 1998 | 25 | 0.160 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 357 | 0.150 |
Why?
|
| Neoplasm Transplantation | 3 | 2008 | 369 | 0.150 |
Why?
|
| CpG Islands | 1 | 2019 | 320 | 0.150 |
Why?
|
| Immunity, Cellular | 2 | 2018 | 202 | 0.150 |
Why?
|
| Analysis of Variance | 7 | 2012 | 1012 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2010 | 82 | 0.150 |
Why?
|
| Mice, Nude | 7 | 2014 | 696 | 0.150 |
Why?
|
| Sodium Chloride | 1 | 2018 | 95 | 0.150 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2018 | 120 | 0.150 |
Why?
|
| Standard of Care | 1 | 2019 | 129 | 0.150 |
Why?
|
| Databases, Genetic | 2 | 2017 | 470 | 0.150 |
Why?
|
| Dasatinib | 2 | 2015 | 40 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2020 | 373 | 0.140 |
Why?
|
| Sexism | 1 | 2017 | 38 | 0.140 |
Why?
|
| Genomic Instability | 1 | 2019 | 229 | 0.140 |
Why?
|
| Hematuria | 2 | 2016 | 53 | 0.140 |
Why?
|
| Mutagens | 1 | 2017 | 84 | 0.140 |
Why?
|
| Genome-Wide Association Study | 3 | 2014 | 1637 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 140 | 0.140 |
Why?
|
| Neutrophils | 2 | 2016 | 372 | 0.140 |
Why?
|
| Tobacco Products | 1 | 2017 | 61 | 0.140 |
Why?
|
| Carcinogens | 1 | 2017 | 153 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2019 | 534 | 0.140 |
Why?
|
| Risk | 4 | 2014 | 747 | 0.140 |
Why?
|
| Blood Cell Count | 1 | 2016 | 69 | 0.140 |
Why?
|
| Laparoscopy | 2 | 2020 | 501 | 0.130 |
Why?
|
| Aurora Kinase A | 1 | 2017 | 39 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 6 | 2005 | 1010 | 0.130 |
Why?
|
| Phospholipids | 1 | 2017 | 107 | 0.130 |
Why?
|
| Urologic Diseases | 1 | 1996 | 44 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2016 | 111 | 0.130 |
Why?
|
| Early Detection of Cancer | 3 | 2017 | 349 | 0.130 |
Why?
|
| Multigene Family | 1 | 2017 | 298 | 0.130 |
Why?
|
| Seminal Vesicles | 3 | 2011 | 55 | 0.130 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 1995 | 31 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2017 | 3087 | 0.130 |
Why?
|
| Membrane Proteins | 3 | 2014 | 1521 | 0.130 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 61 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 3 | 2014 | 158 | 0.130 |
Why?
|
| Blotting, Western | 4 | 2009 | 1102 | 0.130 |
Why?
|
| Interferon-alpha | 1 | 2017 | 221 | 0.130 |
Why?
|
| Celecoxib | 2 | 2014 | 32 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 231 | 0.120 |
Why?
|
| Europe | 1 | 2016 | 349 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 1063 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 152 | 0.120 |
Why?
|
| Mice, Inbred C3H | 3 | 2000 | 118 | 0.120 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 3 | 2003 | 22 | 0.120 |
Why?
|
| Phthalimides | 1 | 2014 | 2 | 0.120 |
Why?
|
| Signal Transduction | 8 | 2024 | 4498 | 0.120 |
Why?
|
| Photoacoustic Techniques | 1 | 2014 | 9 | 0.120 |
Why?
|
| Recombinational DNA Repair | 1 | 2014 | 19 | 0.120 |
Why?
|
| Receptor, TIE-2 | 1 | 2014 | 13 | 0.120 |
Why?
|
| Indazoles | 1 | 2014 | 23 | 0.120 |
Why?
|
| Angiopoietins | 1 | 2014 | 20 | 0.120 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2014 | 25 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2014 | 28 | 0.120 |
Why?
|
| Triglycerides | 1 | 2017 | 562 | 0.120 |
Why?
|
| Dinoprostone | 1 | 2014 | 76 | 0.120 |
Why?
|
| Photosensitizing Agents | 1 | 2014 | 33 | 0.120 |
Why?
|
| Prodrugs | 1 | 2014 | 59 | 0.120 |
Why?
|
| Disease Management | 2 | 2015 | 516 | 0.110 |
Why?
|
| Thalidomide | 1 | 2014 | 36 | 0.110 |
Why?
|
| Sex Factors | 3 | 2014 | 1261 | 0.110 |
Why?
|
| Somatostatin | 2 | 1991 | 71 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 111 | 0.110 |
Why?
|
| Hospitals, High-Volume | 1 | 2014 | 35 | 0.110 |
Why?
|
| Genes, p53 | 3 | 2009 | 213 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2022 | 373 | 0.110 |
Why?
|
| Antigens, Differentiation | 2 | 2005 | 63 | 0.110 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2014 | 42 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2015 | 176 | 0.110 |
Why?
|
| Telomerase | 1 | 2014 | 161 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2014 | 884 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2014 | 65 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2010 | 121 | 0.100 |
Why?
|
| United States Food and Drug Administration | 3 | 2021 | 149 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2003 | 55 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2014 | 197 | 0.100 |
Why?
|
| Plagiarism | 1 | 2012 | 3 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2016 | 199 | 0.100 |
Why?
|
| Chromatography, Liquid | 3 | 2019 | 191 | 0.100 |
Why?
|
| Logistic Models | 5 | 2005 | 1799 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2014 | 178 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 66 | 0.100 |
Why?
|
| Kidney Calculi | 2 | 1991 | 42 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2018 | 1602 | 0.100 |
Why?
|
| Aging | 2 | 1990 | 1185 | 0.100 |
Why?
|
| Editorial Policies | 1 | 2012 | 52 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 142 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 280 | 0.100 |
Why?
|
| Tamoxifen | 3 | 2012 | 363 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 100 | 0.100 |
Why?
|
| Consensus | 3 | 2020 | 612 | 0.100 |
Why?
|
| Liver Transplantation | 3 | 2009 | 1023 | 0.100 |
Why?
|
| Oncolytic Virotherapy | 1 | 2012 | 81 | 0.090 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 624 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 442 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2011 | 62 | 0.090 |
Why?
|
| Medicaid | 1 | 2014 | 243 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 390 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2011 | 48 | 0.090 |
Why?
|
| Contrast Media | 2 | 2018 | 471 | 0.090 |
Why?
|
| Bone Marrow | 3 | 2002 | 326 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2003 | 342 | 0.090 |
Why?
|
| Glycogen | 2 | 2000 | 63 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 524 | 0.090 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1991 | 58 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 261 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2013 | 70 | 0.090 |
Why?
|
| Gluconeogenesis | 2 | 2000 | 108 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 177 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2008 | 4300 | 0.090 |
Why?
|
| Fenretinide | 2 | 2008 | 16 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 263 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2010 | 90 | 0.080 |
Why?
|
| Thiazoles | 1 | 2010 | 97 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 1990 | 173 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 195 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2021 | 1245 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2014 | 94 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 151 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2009 | 145 | 0.080 |
Why?
|
| Biomarkers | 3 | 2023 | 2955 | 0.080 |
Why?
|
| Hypothalamus | 1 | 1991 | 217 | 0.080 |
Why?
|
| Flow Cytometry | 5 | 2005 | 804 | 0.080 |
Why?
|
| ROC Curve | 2 | 2017 | 558 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 141 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 113 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2010 | 169 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 2588 | 0.080 |
Why?
|
| Indolequinones | 1 | 2008 | 1 | 0.080 |
Why?
|
| Quality of Life | 3 | 2014 | 1936 | 0.080 |
Why?
|
| H-2 Antigens | 1 | 1988 | 24 | 0.080 |
Why?
|
| Estrus | 1 | 1988 | 14 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 2 | 2024 | 216 | 0.080 |
Why?
|
| Aziridines | 1 | 2008 | 11 | 0.080 |
Why?
|
| Estradiol | 2 | 2012 | 544 | 0.080 |
Why?
|
| Texas | 5 | 2017 | 3558 | 0.070 |
Why?
|
| Ureteroscopy | 2 | 2019 | 17 | 0.070 |
Why?
|
| Hernia, Abdominal | 1 | 2008 | 18 | 0.070 |
Why?
|
| Probability | 3 | 2012 | 321 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 1988 | 312 | 0.070 |
Why?
|
| Drug Administration Schedule | 7 | 2012 | 726 | 0.070 |
Why?
|
| Morbidity | 1 | 2008 | 241 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2008 | 102 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 767 | 0.070 |
Why?
|
| Surgical Mesh | 1 | 2008 | 62 | 0.070 |
Why?
|
| Carbon Radioisotopes | 1 | 2007 | 71 | 0.070 |
Why?
|
| Cause of Death | 3 | 2005 | 463 | 0.070 |
Why?
|
| Computational Biology | 3 | 2017 | 804 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 1991 | 2530 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 60 | 0.070 |
Why?
|
| Immediate-Early Proteins | 2 | 2012 | 58 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 237 | 0.070 |
Why?
|
| Cyclin D1 | 2 | 2012 | 112 | 0.070 |
Why?
|
| Global Health | 2 | 2008 | 546 | 0.070 |
Why?
|
| Actuarial Analysis | 3 | 2001 | 30 | 0.070 |
Why?
|
| Caveolin 1 | 1 | 2006 | 46 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2003 | 743 | 0.070 |
Why?
|
| Urology | 2 | 2020 | 74 | 0.070 |
Why?
|
| Selenomethionine | 1 | 2006 | 14 | 0.070 |
Why?
|
| Selenium | 1 | 2006 | 22 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2017 | 401 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 788 | 0.070 |
Why?
|
| Life Tables | 3 | 2001 | 29 | 0.060 |
Why?
|
| Drainage | 1 | 2007 | 257 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 409 | 0.060 |
Why?
|
| Fertility | 1 | 1988 | 263 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 374 | 0.060 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2005 | 13 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2006 | 232 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2009 | 364 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 329 | 0.060 |
Why?
|
| Genotype | 5 | 2013 | 2539 | 0.060 |
Why?
|
| Cell Movement | 3 | 2017 | 831 | 0.060 |
Why?
|
| Calcium Oxalate | 1 | 2005 | 24 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 1312 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 79 | 0.060 |
Why?
|
| Transfection | 2 | 2004 | 1068 | 0.060 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2005 | 39 | 0.060 |
Why?
|
| Antigens, CD | 3 | 2005 | 420 | 0.060 |
Why?
|
| Insemination, Artificial | 2 | 2003 | 13 | 0.060 |
Why?
|
| Androstenes | 1 | 2024 | 5 | 0.060 |
Why?
|
| Phenotype | 4 | 2017 | 4225 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 3553 | 0.060 |
Why?
|
| Electron Transport Complex I | 1 | 2024 | 31 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2005 | 41 | 0.060 |
Why?
|
| Nutritional Status | 1 | 2006 | 305 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2007 | 465 | 0.060 |
Why?
|
| Cancer Pain | 1 | 2024 | 23 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1915 | 0.060 |
Why?
|
| Autocrine Communication | 1 | 2004 | 27 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 9 | 4 | 2003 | 106 | 0.060 |
Why?
|
| SMARCB1 Protein | 1 | 2024 | 37 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2010 | 538 | 0.060 |
Why?
|
| Carotenoids | 1 | 2004 | 75 | 0.060 |
Why?
|
| Cytodiagnosis | 1 | 2003 | 19 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2019 | 697 | 0.060 |
Why?
|
| Centrosome | 1 | 2003 | 34 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2009 | 630 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2005 | 224 | 0.050 |
Why?
|
| Calcinosis | 1 | 2005 | 170 | 0.050 |
Why?
|
| Sperm-Ovum Interactions | 1 | 2003 | 24 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 1998 | 644 | 0.050 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 84 | 0.050 |
Why?
|
| Chemical Industry | 1 | 2003 | 7 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1289 | 0.050 |
Why?
|
| 2-Naphthylamine | 1 | 2003 | 6 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 19 | 0.050 |
Why?
|
| Fertilization | 1 | 2003 | 43 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2015 | 754 | 0.050 |
Why?
|
| Creatinine | 1 | 2005 | 382 | 0.050 |
Why?
|
| Vehicle Emissions | 1 | 2023 | 19 | 0.050 |
Why?
|
| SEER Program | 2 | 2016 | 194 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2004 | 318 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2003 | 93 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 179 | 0.050 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 664 | 0.050 |
Why?
|
| Leukemic Infiltration | 1 | 2002 | 8 | 0.050 |
Why?
|
| Exons | 1 | 2005 | 794 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 502 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2004 | 170 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2001 | 254 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 154 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2022 | 48 | 0.050 |
Why?
|
| Organothiophosphorus Compounds | 1 | 2001 | 1 | 0.050 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 309 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 1 | 2001 | 2 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2001 | 37 | 0.050 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2003 | 193 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 207 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2001 | 58 | 0.050 |
Why?
|
| Angiomyolipoma | 1 | 2001 | 3 | 0.050 |
Why?
|
| Research Design | 1 | 2005 | 679 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2003 | 317 | 0.050 |
Why?
|
| Leukemia, B-Cell | 1 | 2001 | 26 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2001 | 34 | 0.050 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2001 | 24 | 0.050 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2000 | 26 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2001 | 73 | 0.050 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2000 | 17 | 0.050 |
Why?
|
| Pain | 1 | 2024 | 470 | 0.050 |
Why?
|
| Ketoglutaric Acids | 1 | 2000 | 24 | 0.050 |
Why?
|
| Retreatment | 1 | 2021 | 88 | 0.050 |
Why?
|
| Ploidies | 1 | 2000 | 37 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 133 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 620 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 618 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2023 | 264 | 0.040 |
Why?
|
| Embryo, Nonmammalian | 1 | 2000 | 142 | 0.040 |
Why?
|
| Herpesviridae | 1 | 2000 | 31 | 0.040 |
Why?
|
| Uric Acid | 1 | 2000 | 93 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2016 | 402 | 0.040 |
Why?
|
| Glucuronic Acid | 1 | 2019 | 13 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 16 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 291 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 30 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2017 | 756 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 39 | 0.040 |
Why?
|
| Biomedical Technology | 1 | 2020 | 35 | 0.040 |
Why?
|
| Organ Size | 1 | 2000 | 419 | 0.040 |
Why?
|
| Neoplasms | 1 | 2014 | 2759 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2000 | 56 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 129 | 0.040 |
Why?
|
| Survivors | 2 | 2014 | 344 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2001 | 172 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 51 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2019 | 62 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 2001 | 121 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 36 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 285 | 0.040 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 1989 | 52 | 0.040 |
Why?
|
| Mortality | 1 | 2000 | 228 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 194 | 0.040 |
Why?
|
| Embryonic Development | 1 | 2000 | 209 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 110 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 716 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 995 | 0.040 |
Why?
|
| DNA | 2 | 2023 | 1596 | 0.040 |
Why?
|
| Health Personnel | 1 | 2023 | 493 | 0.040 |
Why?
|
| Alleles | 3 | 2014 | 1601 | 0.040 |
Why?
|
| Rats | 6 | 2008 | 3668 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2001 | 218 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 2053 | 0.040 |
Why?
|
| Prevalence | 1 | 2005 | 2409 | 0.040 |
Why?
|
| Retinoids | 1 | 1998 | 33 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 518 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2000 | 436 | 0.040 |
Why?
|
| Registries | 2 | 2016 | 1398 | 0.040 |
Why?
|
| Algorithms | 3 | 2017 | 1596 | 0.040 |
Why?
|
| Inflammation | 1 | 2005 | 1404 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 1998 | 78 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 947 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 177 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2058 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 2861 | 0.040 |
Why?
|
| Informed Consent | 1 | 2001 | 342 | 0.040 |
Why?
|
| Butanones | 1 | 2017 | 7 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 228 | 0.040 |
Why?
|
| Recurrence | 2 | 2014 | 1419 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 24 | 0.040 |
Why?
|
| Nitrosamines | 1 | 2017 | 18 | 0.040 |
Why?
|
| Disaccharides | 1 | 2017 | 13 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 19 | 0.040 |
Why?
|
| Urination Disorders | 1 | 2017 | 18 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 2 | 1998 | 577 | 0.040 |
Why?
|
| Cholic Acids | 1 | 2017 | 16 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2010 | 279 | 0.040 |
Why?
|
| Azacitidine | 1 | 2017 | 54 | 0.040 |
Why?
|
| Nitrogenous Group Transferases | 1 | 2017 | 4 | 0.040 |
Why?
|
| Phosphatidylethanolamines | 1 | 2017 | 22 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 866 | 0.040 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 26 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 1997 | 47 | 0.040 |
Why?
|
| DNA Adducts | 1 | 2017 | 78 | 0.040 |
Why?
|
| Diglycerides | 1 | 2017 | 18 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2017 | 30 | 0.040 |
Why?
|
| Splenectomy | 1 | 1997 | 60 | 0.040 |
Why?
|
| Sequence Analysis, Protein | 1 | 2017 | 49 | 0.040 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1997 | 34 | 0.040 |
Why?
|
| Observer Variation | 1 | 2018 | 300 | 0.040 |
Why?
|
| Prednisone | 2 | 1998 | 274 | 0.040 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2016 | 5 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2017 | 46 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 389 | 0.030 |
Why?
|
| Remission Induction | 4 | 2002 | 299 | 0.030 |
Why?
|
| Aristolochic Acids | 1 | 2016 | 1 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2018 | 133 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2017 | 68 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 1385 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 1997 | 78 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 220 | 0.030 |
Why?
|
| Ileum | 1 | 1997 | 132 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 142 | 0.030 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2017 | 67 | 0.030 |
Why?
|
| Lewis X Antigen | 1 | 2016 | 11 | 0.030 |
Why?
|
| Stents | 1 | 2023 | 877 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 313 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2019 | 246 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 1998 | 295 | 0.030 |
Why?
|
| Cytosine | 1 | 1996 | 56 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 1996 | 19 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2017 | 102 | 0.030 |
Why?
|
| Fatigue | 1 | 2017 | 218 | 0.030 |
Why?
|
| Heart | 1 | 2000 | 723 | 0.030 |
Why?
|
| Age Factors | 3 | 2012 | 2808 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2000 | 774 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 247 | 0.030 |
Why?
|
| Orchiectomy | 1 | 1995 | 49 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 3 | 1991 | 396 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 440 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2016 | 118 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2010 | 862 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 79 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 208 | 0.030 |
Why?
|
| Molecular Epidemiology | 2 | 2006 | 155 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1995 | 107 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 2591 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 28 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2014 | 30 | 0.030 |
Why?
|
| Cerebrosides | 1 | 2014 | 4 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 28 | 0.030 |
Why?
|
| Hematoma | 1 | 1995 | 92 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 865 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 715 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 350 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 470 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 475 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 205 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 178 | 0.030 |
Why?
|
| Peer Review | 1 | 2014 | 40 | 0.030 |
Why?
|
| Chromosome Deletion | 2 | 1994 | 640 | 0.030 |
Why?
|
| Liver | 1 | 2000 | 1743 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1014 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 1996 | 286 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 172 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 433 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 153 | 0.030 |
Why?
|
| Proteins | 1 | 1998 | 1040 | 0.030 |
Why?
|
| Asparaginase | 1 | 1993 | 41 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 1997 | 543 | 0.030 |
Why?
|
| Scientific Misconduct | 1 | 2012 | 6 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2012 | 17 | 0.030 |
Why?
|
| Metestrus | 1 | 1992 | 1 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 3681 | 0.030 |
Why?
|
| Substantia Nigra | 2 | 1989 | 32 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 4361 | 0.030 |
Why?
|
| Reference Values | 2 | 2007 | 701 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 158 | 0.030 |
Why?
|
| Fever | 3 | 2001 | 296 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2012 | 133 | 0.030 |
Why?
|
| Young Adult | 3 | 2010 | 8871 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2012 | 103 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 805 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 1613 | 0.020 |
Why?
|
| MCF-7 Cells | 1 | 2012 | 221 | 0.020 |
Why?
|
| Keratins | 1 | 2012 | 55 | 0.020 |
Why?
|
| Ovariectomy | 1 | 1992 | 182 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1992 | 197 | 0.020 |
Why?
|
| Lymphoma, Follicular | 2 | 2002 | 29 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 940 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 1550 | 0.020 |
Why?
|
| Administration, Metronomic | 1 | 2011 | 1 | 0.020 |
Why?
|
| Ovarian Follicle | 1 | 1992 | 119 | 0.020 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 1991 | 19 | 0.020 |
Why?
|
| Lithotripsy | 1 | 1991 | 22 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 1993 | 221 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1993 | 371 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2001 | 62 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1701 | 0.020 |
Why?
|
| International Agencies | 1 | 2011 | 28 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 2398 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 197 | 0.020 |
Why?
|
| Diencephalon | 1 | 1991 | 10 | 0.020 |
Why?
|
| Wound Healing | 1 | 2014 | 454 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 233 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 461 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2017 | 827 | 0.020 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 1991 | 58 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2003 | 219 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2011 | 176 | 0.020 |
Why?
|
| Rituximab | 2 | 2001 | 155 | 0.020 |
Why?
|
| Glucagon | 1 | 1990 | 185 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2010 | 37 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 137 | 0.020 |
Why?
|
| Prednisolone | 2 | 2001 | 72 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 458 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2001 | 539 | 0.020 |
Why?
|
| Lymphoma | 1 | 1993 | 322 | 0.020 |
Why?
|
| Ribonucleotide Reductases | 1 | 2009 | 10 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 2002 | 422 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2009 | 21 | 0.020 |
Why?
|
| Leukemia | 1 | 1993 | 375 | 0.020 |
Why?
|
| Prostatic Diseases | 1 | 1989 | 15 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 58 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 1878 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 64 | 0.020 |
Why?
|
| Selection Bias | 1 | 2009 | 20 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2008 | 1218 | 0.020 |
Why?
|
| Palliative Care | 1 | 1992 | 428 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2010 | 130 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 130 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2009 | 150 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 1988 | 13 | 0.020 |
Why?
|
| Loss of Heterozygosity | 2 | 1999 | 124 | 0.020 |
Why?
|
| Cysts | 1 | 1989 | 100 | 0.020 |
Why?
|
| Corticosterone | 1 | 1988 | 59 | 0.020 |
Why?
|
| Cyclin E | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 58 | 0.020 |
Why?
|
| Cell Count | 1 | 1988 | 251 | 0.020 |
Why?
|
| Models, Biological | 2 | 2006 | 1453 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1990 | 577 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 356 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 526 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 1988 | 122 | 0.020 |
Why?
|
| Dopamine | 1 | 1989 | 284 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 241 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 137 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 470 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2013 | 517 | 0.020 |
Why?
|
| Fetus | 1 | 1991 | 575 | 0.020 |
Why?
|
| Radioimmunoassay | 2 | 2000 | 110 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2007 | 227 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 254 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 2 | 1998 | 230 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 488 | 0.020 |
Why?
|
| Oocytes | 1 | 1988 | 290 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 1591 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2008 | 176 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3385 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 87 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2005 | 51 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 383 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2005 | 91 | 0.020 |
Why?
|
| Comet Assay | 1 | 2004 | 11 | 0.020 |
Why?
|
| Food Analysis | 1 | 2005 | 26 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2005 | 232 | 0.010 |
Why?
|
| Genes | 1 | 2006 | 444 | 0.010 |
Why?
|
| Gamma Rays | 1 | 2004 | 49 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 999 | 0.010 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2004 | 16 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2004 | 37 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 294 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 1567 | 0.010 |
Why?
|
| Infant | 2 | 2000 | 12371 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2005 | 209 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 410 | 0.010 |
Why?
|
| Swine | 1 | 2008 | 1167 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1989 | 943 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2000 | 13928 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 586 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 671 | 0.010 |
Why?
|
| Image Cytometry | 1 | 2003 | 13 | 0.010 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2004 | 125 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2478 | 0.010 |
Why?
|
| Adolescent | 3 | 2000 | 19129 | 0.010 |
Why?
|
| Breeding | 1 | 2003 | 20 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2003 | 58 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 1317 | 0.010 |
Why?
|
| Tubulin | 1 | 2003 | 102 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 684 | 0.010 |
Why?
|
| Fruit | 1 | 2005 | 221 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 330 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 783 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2003 | 154 | 0.010 |
Why?
|
| Vegetables | 1 | 2005 | 261 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 667 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2002 | 14 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 8116 | 0.010 |
Why?
|
| Hippocampus | 1 | 1988 | 819 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2002 | 99 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 2001 | 11 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2001 | 4 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2001 | 16 | 0.010 |
Why?
|
| Cadaver | 1 | 2001 | 129 | 0.010 |
Why?
|
| Chills | 1 | 2001 | 6 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 229 | 0.010 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2001 | 28 | 0.010 |
Why?
|
| Lymphocytosis | 1 | 2001 | 14 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 115 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2001 | 32 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 810 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2001 | 93 | 0.010 |
Why?
|
| Dyspnea | 1 | 2001 | 149 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2001 | 290 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 1581 | 0.010 |
Why?
|
| Child | 2 | 2000 | 24269 | 0.010 |
Why?
|
| Hypoxia | 1 | 2001 | 248 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2000 | 229 | 0.010 |
Why?
|
| Rats, Inbred F344 | 2 | 1989 | 105 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2004 | 708 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 412 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2001 | 402 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1998 | 85 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2001 | 225 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2001 | 495 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 1998 | 55 | 0.010 |
Why?
|
| Pregnancy | 1 | 1991 | 7129 | 0.010 |
Why?
|
| Monocytes | 1 | 2000 | 345 | 0.010 |
Why?
|
| Mass Screening | 1 | 2003 | 779 | 0.010 |
Why?
|
| Anemia | 1 | 2001 | 341 | 0.010 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1997 | 86 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1999 | 528 | 0.010 |
Why?
|
| Neutropenia | 1 | 1997 | 202 | 0.010 |
Why?
|
| Seminoma | 1 | 1995 | 8 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 294 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2000 | 1013 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1997 | 659 | 0.010 |
Why?
|
| Fever of Unknown Origin | 1 | 1995 | 45 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1995 | 147 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 328 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 1998 | 645 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1993 | 56 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1995 | 768 | 0.010 |
Why?
|
| Skin | 1 | 1995 | 507 | 0.010 |
Why?
|
| Pneumonia | 1 | 1995 | 325 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1995 | 327 | 0.010 |
Why?
|
| Bacteremia | 1 | 1995 | 405 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1993 | 1082 | 0.010 |
Why?
|
| Hydroxydopamines | 1 | 1989 | 5 | 0.010 |
Why?
|
| Reserpine | 1 | 1989 | 12 | 0.010 |
Why?
|
| Oxidopamine | 1 | 1989 | 15 | 0.010 |
Why?
|
| Genital Diseases, Male | 1 | 1989 | 12 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1993 | 334 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 3090 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1993 | 376 | 0.010 |
Why?
|
| Mullerian Ducts | 1 | 1989 | 40 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3868 | 0.000 |
Why?
|